Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAURA: Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC
NCT04351555Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04351555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351555.